{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-22-000002","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-01-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.416561+00:00","generated_at":"2026-06-27T15:19:45.974116+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Edwards Q4 sales $1.33B (+12% YoY); adjusted EPS $0.51; guides FY22 sales $5.5-6.0B","bullets":["Q4 sales $1.33B, up 12% (13% underlying); TAVR sales $872M (+12%); TMTT $25M.","Q4 GAAP EPS $0.53; adjusted EPS $0.51.","Full year 2021 sales $5.2B (+19%); adjusted EPS $2.22 (+19% YoY).","FY22 guidance: sales $5.5-6.0B (low double-digit growth); adjusted EPS $2.50-$2.65; Q1 sales $1.27-1.35B.","Completed enrollment of CLASP IID and EARLY TAVR trials; FDA approved SAPIEN 3 with Alterra."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-22-000002","json":"https://secwatch.observer/filing/0001099800-22-000002.json","markdown":"https://secwatch.observer/filing/0001099800-22-000002.md","text":"https://secwatch.observer/filing/0001099800-22-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/0001099800-22-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000002/ew-20220126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:19:45.974116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}